Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-08-12
Zachary Jennifer Files Merck & Co. (MRK) Form 4 - August 12, 2026
Zachary Jennifer traded 135.2K MRK shares worth $16.7M in this Form 4 filing, reported to the SEC on 2026-08-12.
- Insider
- Zachary Jennifer
- Issuer
- Merck & Co., Inc. MRK · NYSE
- Filed
- Period
- 2026-08-12
- Accession
- 0000310158-26-000221
- Source
- Official filing on sec.gov ↗
Transactions (5)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Zachary Jennifer | 2026-08-12 | Buy | 41.5K | $117.89 | $4.9M | Direct |
| Zachary Jennifer | 2026-08-12 | Buy | 13.4K | $84.71 | $1.1M | Direct |
| Zachary Jennifer | 2026-08-12 | Sell | 80.3K | $133.46 | $10.7M | Direct |
| Net change | −25.4K | −$4.7M | ||||
About Merck & Co., Inc.
Merck & Co., Inc. is a prominent player in the global pharmaceutical industry. It is primarily focused on the research, development, production, and marketing of drugs and vaccines. Known for its strong emphasis on innovative health solutions, Merck develops treatments and vaccines for a variety of diseases affecting humans and animals. Key areas include oncology, infectious diseases, diabetes, and vaccines, reflecting its commitment to addressing critical health challenges worldwide. The company operates in several strategic regions, exporting its advanced therapies to meet healthcare needs across different markets. With a robust pipeline of new products and significant investment in research and development, Merck plays a vital role in advancing medical breakthroughs and enhancing patient care. Beyond pharmaceuticals, Merck is involved in animal health, providing veterinary vaccines and services, contributing to agricultural productivity and food security. The company's ongoing efforts in groundbreaking research and public health initiatives underscore its importance in the healthcare sector.
Track MRK insider activity
Get alerted when Merck & Co., Inc. executives buy or sell their shares.